Benefit–Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm

  1. Citrome, L.
  2. Sánchez del Rio, M.
  3. Dong, Y.
  4. Nichols, R.M.
  5. Tockhorn-Heidenreich, A.
  6. Foster, S.A.
  7. Stauffer, V.L.
Revista:
Advances in Therapy

ISSN: 1865-8652,  0741-238X

Any de publicació: 2021

Volum: 38

Número: 8

Pàgines: 4442-4460

Tipus: Article

DOI: 10.1007/S12325-021-01848-X GOOGLE SCHOLAR lock_openAccés obert editor
Font de les dades: Scopus